Abstract: A steering wheel for a motor vehicle is provided. The steering wheel comprises a steering wheel rim, a hub body via which the steering wheel can be mounted rotarily around a steering axle on a motor vehicle and at least one spoke via which the hub body is connected to the steering wheel rim. The at least one spoke is designed to be adjustable with respect to the steering wheel rim.

Abstract: An airbag arrangement for a vehicle occupant restraint system includes an inflatable airbag having at least one outflow opening through which gas can flow out of the airbag. The airbag arrangement also includes a stretchable element including a covering structure for adjustably covering a portion of the outflow opening. The covering structure moves relative to the outflow opening when the stretchable element is stretched. The airbag arrangement also includes a fastener for fastening the stretchable element to the airbag so the stretchable element stretches when the airbag inflates and the covering structure moves relative to the outflow opening changing the size of the covered portion of the outflow opening.

Abstract: An airbag arrangement for a vehicle occupant restraint system includes an inflatable airbag having at least one outflow opening through which gas can flow out of the airbag. The airbag arrangement also includes a stretchable element including a covering structure for adjustably covering a portion of the outflow opening. The covering structure moves relative to the outflow opening when the stretchable element is stretched. The airbag arrangement also includes a fastener for fastening the stretchable element to the airbag so the stretchable element stretches when the airbag inflates and the covering structure moves relative to the outflow opening changing the size of the covered portion of the outflow opening.

Abstract: The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.

Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.

Abstract: The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.

Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.

Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.

Abstract: The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.

Abstract: The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.